<DOC>
	<DOCNO>NCT00160615</DOCNO>
	<brief_summary>The safety efficacy L059 evaluate patient complete `` N165 Clinical Trial L059 '' . They receive L059 daily dose 1,000 mg 3,000 mg addition standard concomitant AEDs</brief_summary>
	<brief_title>Follow-up Study L059 ( Levetiracetam ) Epileptic Patients With Partial Onset Seizures Open Label Method</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>1 . Patients complete evaluation period ( Week 16 ) N165 Clinical Trial L059 2 . Patients/the parent guardian wish continue treatment L059 enter N165 Followup Study , also investigator admit necessity repeat intake investigational drug patient . 1 . Patients participate N165 Clinical Trial L059 . 2 . Patients participate N165 Clinical Trial L059 intention enter followup study take medication . 3 . Patients compliance requirement Protocol N165 Clinical Trial L059 course study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Epilepsy , Partial ,</keyword>
	<keyword>Keppra , levetiracetam</keyword>
</DOC>